Search - tctmd.com

Displaying 161 - 180 of 508

Sort: Relevancy | Date

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

November 18, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

ACC/AHA Release Updated Aortic Disease Guideline

News Daily News

ACC/AHA Release Updated Aortic Disease Guideline

November 02, 2022

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

November 01, 2022

TCTMD’s Top 10 Most Popular Stories for October 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2022

October 31, 2022

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

News Daily News

Hints of Benefit With Catheter-Directed Thrombolysis in Intermediate/High-Risk PE

October 19, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

Two RCTs Add Needed Evidence for Thrombectomy in Basilar Occlusion

News Daily News

Two RCTs Add Needed Evidence for Thrombectomy in Basilar Occlusion

October 13, 2022

TCTMD’s Top 10 Most Popular Stories for September 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2022

October 03, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

September 2022 News Roundup

News Opinion CV Team Dispatch

September 2022 News Roundup

September 01, 2022

TCTMD’s Top 10 Most Popular Stories for August 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2022

September 01, 2022

International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches - Chronic Kidney Disease EXTENDed Follow-up: Survival at 5 years of Follow-up

Presentation ESC 2022

International Study Of Comparative Health Effectiveness With Medical And Invasive Approaches - Chronic Kidney Disease EXTENDed Follow-up: Survival at 5 years of Follow-up

Presenter: Sripal Bangalore

August 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.